DexCom (DXCM) Projected to Post Earnings on Thursday

DexCom (NASDAQ:DXCM - Get Free Report) is expected to release its Q1 2025 earnings data after the market closes on Thursday, May 1st. Analysts expect DexCom to post earnings of $0.33 per share and revenue of $1.02 billion for the quarter.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, analysts expect DexCom to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

DexCom Price Performance

DXCM stock traded up $0.88 during trading on Friday, hitting $71.66. The company had a trading volume of 2,857,981 shares, compared to its average volume of 4,219,647. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. The company has a fifty day moving average price of $73.09 and a two-hundred day moving average price of $76.63. DexCom has a fifty-two week low of $57.52 and a fifty-two week high of $132.26. The company has a market cap of $28.10 billion, a P/E ratio of 50.11, a P/E/G ratio of 2.30 and a beta of 1.50.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Morgan Stanley increased their target price on shares of DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a research report on Friday, February 14th. Citigroup lifted their target price on shares of DexCom from $101.00 to $104.00 and gave the company a "buy" rating in a research note on Tuesday, March 4th. Canaccord Genuity Group boosted their target price on DexCom from $99.00 to $103.00 and gave the stock a "buy" rating in a report on Friday, February 14th. Baird R W raised DexCom from a "hold" rating to a "strong-buy" rating in a report on Thursday, January 16th. Finally, Cfra Research raised DexCom to a "hold" rating in a research note on Friday, March 21st. Five analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat.com, DexCom presently has an average rating of "Moderate Buy" and a consensus target price of $99.00.

Insiders Place Their Bets

In other news, COO Jacob Steven Leach sold 14,076 shares of the business's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $990,668.88. Following the completion of the transaction, the chief operating officer now owns 313,497 shares of the company's stock, valued at $22,063,918.86. The trade was a 4.30 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Michael Jon Brown sold 13,000 shares of the firm's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $914,940.00. Following the sale, the executive vice president now directly owns 105,602 shares in the company, valued at $7,432,268.76. The trade was a 10.96 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 105,009 shares of company stock worth $8,044,178. Insiders own 0.32% of the company's stock.

Hedge Funds Weigh In On DexCom

An institutional investor recently raised its position in DexCom stock. Brighton Jones LLC raised its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 257.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 16,582 shares of the medical device company's stock after buying an additional 11,946 shares during the quarter. Brighton Jones LLC's holdings in DexCom were worth $1,290,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 97.75% of the company's stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.